Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193258
Status:
COMPLETED
Last Update Posted:
2013-01-31
First Post:
2005-09-12
Brief Title:
Bevacizumab Erlotinib and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase III Trial of Bevacizumab Avastin Erlotinib Tarceva and Imatinib Gleevec in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase III trial will evaluate the bevacizumaberlotinib combination with the addition of imatinib Gleevec The combined inhibition greatly enhances the anti-tumor effects Although the safety of the bevacizumaberlotinibimatinib combination has not yet been demonstrated the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity A brief phase I portion will be included in this trial to optimize doses of the 3 agents prior to proceeding with the phase II trial
Detailed Description:
Upon determination of eligibility patients will be receive
Bevacizumab Erlotinib Imatinib
A brief phase I dose escalation study will be performed to define the imatinib dose that will be used
Bevacizumab Erlotinib Imatinib
A brief phase I dose escalation study will be performed to define the imatinib dose that will be used
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None